US patent for the preparation, storage, and dispensing of compounded suppositories
WOBURN, Mass., Nov. 6 /PRNewswire/ -- CutisPharma, Inc. today announced that it has received approval from the United States Patent and Trademark Office for its patent (US 7,434,690) regarding a container and kit for the preparation, storage and dispensing of compounded suppositories.
"By its very nature, the process of compounding suppositories is cumbersome, time-consuming and in general, without adequate compensation" said Dr. Indu Muni, founder, chairman, and CEO of CutisPharma, Inc. "Our container (suppository mold) and the method for suppository-compounding is user-friendly and time saving for a pharmacy. Our suppository mold is also customer friendly because the take-home molds are especially designed to not only maintain the integrity of each suppository once compounded, but also provide convenient dispensing tools", he added.
Currently CutisPharma has FIRST(R) Progesterone Vaginal Suppository Unit-of-Use Prescription Compounding Kit product line available, which uses the patented container. The line includes FIRST(R) - Progesterone VGS 25, 50, 100, 200 and 400 representing various strengths (mg.). The kits are made for a single patient and include pre-weighed progesterone, and suppository base, and the patented disposable container/mold for preparation, storage, and dispensing of the suppositories. A single NDC number assigned for the entire kit aids the third party reimbursement process, reduces audit- related adjustments, and the use of these FIRST(R) kits facilitates compliance with USP Chapter <795>. This patented container, kit, and the method will also be used for future suppository compounding kits such as Boric Acid, Morphine, and others.
CutisPharma estimates that over 1.5 million progesterone suppository
prescriptions are written in the U.S. annually, representing a potential of
nearly $100 million at the retail level. The Kit allo
|SOURCE CutisPharma, Inc.|
Copyright©2008 PR Newswire.
All rights reserved